Skip to content
Catalyst

azithromycinWhat was measured

Measured, with no finding

304 endpoints

Show what was measuredHide what was measured
  • all-cause mortality, Bayesian pooled relative risk

    no effect

    pooled RR for mortality of 0.93 (95% CI 0.72–1.14, n = 17 studies)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, Bayesian pooled relative risk

    no effect

    pooled RR for mortality of 1.32 (95% CI 0.97–1.68, n = 7 studies)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, pooled relative risk, observational studies with moderate risk of bias

    no effect

    RRmoderate bias = 1.03 (95% CI 0.91–1.17

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, pooled relative risk, sensitivity analysis including critical-risk studies

    no effect

    the global RR was marginally not significant 0.80 (95% CI 0.65–1.00)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, pooled relative risk

    no effect

    All studies | 17 | 0.83 (0.65–1.06) | -4.4% (–9% to +1.5%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, pooled relative risk

    increases

    All studies | 7 | 1.27 (1.04–1.54) | +7% (+1% to +14%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, pooled relative risk

    no effect

    Non-randomized studies | 14 | 0.79 (0.60–1.04) | -5.5% (–10% to +1%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, pooled relative risk

    no effect

    Randomized studies | 3 | 1.09 (0.97–1.24) | +2.3% (–0.8% to +6.2%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, pooled relative risk

    increases

    Non-randomized studies | 6 | 1.29 (1.06–1.58) | +7.5% (+1.6% to +15%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, pooled relative risk

    no effect

    Randomized studies | 1 | 0.64 (0.18–2.24) | -9% (–21% to +32%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, risk difference

    no effect

    All studies | 17 | 0.83 (0.65–1.06) | -4.4% (–9% to +1.5%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, risk difference

    increases

    All studies | 7 | 1.27 (1.04–1.54) | +7% (+1% to +14%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, risk difference

    no effect

    Non-randomized studies | 14 | 0.79 (0.60–1.04) | -5.5% (–10% to +1%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, risk difference

    no effect

    Randomized studies | 3 | 1.09 (0.97–1.24) | +2.3% (–0.8% to +6.2%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, risk difference

    increases

    Non-randomized studies | 6 | 1.29 (1.06–1.58) | +7.5% (+1.6% to +15%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, risk difference

    no effect

    Randomized studies | 1 | 0.64 (0.18–2.24) | -9% (–21% to +32%)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, subgroup difference randomized vs non-randomized

    p = 0.03

    (Pheterogeneity between = 0.03)

    PMID 32860962 · one of two readings recorded this

  • all-cause mortality, subgroup difference randomized vs non-randomized

    no effect, p = 0.28

    (Pheterogeneity between = 0.28)

    PMID 32860962 · one of two readings recorded this

  • COVID-19 mortality, pooled relative risk, hydroxychloroquine with azithromycin versus standard of care (all-cause mortality per Table 1)

    increases, RR 1.27 (95% CI 1.04-1.54, n = 7 studies), n = 7

    Not recorded as a finding: the intervention held more than the compound

    After exclusion of studies with critical bias, the pooled RR for COVID-19 mortality was 1.27 (95% CI 1.04–1.54, n = 7), indicating an increased mortality linked to the use of hydroxychloroquine with azithromycin.

    PMID 32860962 · one of two readings recorded this

  • COVID-19 mortality, pooled relative risk, hydroxychloroquine with azithromycin versus standard of care (studies at critical risk of bias excluded)

    increases, pooled RR 1.27 (95% CI 1.04-1.54, n = 7), n = 7

    Not recorded as a finding: the intervention held more than the compound

    After exclusion of studies with critical bias, the pooled RR for COVID-19 mortality was 1.27 (95% CI 1.04–1.54, n = 7), indicating an increased mortality linked to the use of hydroxychloroquine with azithromycin.

    PMID 32860962 · one of two readings recorded this

  • deaths, hydroxychloroquine group

    with 3152 deaths, 1063 deaths and 2857 deaths, respectively

    PMID 32860962 · one of two readings recorded this

  • deaths, hydroxychloroquine with azithromycin group

    with 3152 deaths, 1063 deaths and 2857 deaths, respectively

    PMID 32860962 · one of two readings recorded this

  • deaths, standard of care group

    with 3152 deaths, 1063 deaths and 2857 deaths, respectively

    PMID 32860962 · one of two readings recorded this

  • publication bias, Begg's test

    no effect, p = 0.13

    Begg's test (p 0.13)

    PMID 32860962 · one of two readings recorded this

  • publication bias, Begg's test

    no effect, p = 0.65

    Begg's test (p 0.65)

    PMID 32860962 · one of two readings recorded this

  • publication bias, Egger's test

    no effect, p = 0.68

    Egger's test (p 0.68)

    PMID 32860962 · one of two readings recorded this

  • publication bias, Egger's test

    no effect, p = 0.7

    Egger's test (p 0.70)

    PMID 32860962 · one of two readings recorded this

  • prevalence of peak QTc >=500 ms

    was 9% (95% confidence interval [95%CI], 3%-18%)

    PMID 33772933 · one of two readings recorded this

  • prevalence of peak QTc >=500 ms

    8% (95%CI, 3%-14%)

    PMID 33772933 · one of two readings recorded this

  • QTc prolongation (peak QTc >=500 ms, peak QTc change >=60 ms) in COVID-19 patients, pooled risk ratio versus no treatment

    increases, RR 3.28; 95%CI 1.16-9.30 for hydroxychloroquine + azithromycin

    Not recorded as a finding: the intervention held more than the compound

    Likewise, the use of hydroxychloroquine (risk ratio [RR], 2.68; 95%CI, 1.56-4.60) and hydroxychloroquine + azithromycin (RR, 3.28; 95%CI, 1.16-9.30) was associated with an increased risk of QTc prolongation compared to no treatment.

    PMID 33772933 · one of two readings recorded this

  • risk of QTc prolongation in COVID-19 patients (peak QTc 500 ms or more, peak QTc change 60 ms or more), pooled risk ratio versus no treatment; abstract only

    increases, hydroxychloroquine + azithromycin RR, 3.28; 95%CI, 1.16-9.30

    Not recorded as a finding: the intervention held more than the compound

    Likewise, the use of hydroxychloroquine (risk ratio [RR], 2.68; 95%CI, 1.56-4.60) and hydroxychloroquine + azithromycin (RR, 3.28; 95%CI, 1.16-9.30) was associated with an increased risk of QTc prolongation compared to no treatment.

    PMID 33772933 · one of two readings recorded this

  • risk of QTc prolongation versus no treatment

    increases

    hydroxychloroquine + azithromycin (RR, 3.28; 95%CI, 1.16-9.30)

    PMID 33772933 · one of two readings recorded this

  • risk of QTc prolongation versus no treatment

    increases

    the use of hydroxychloroquine (risk ratio [RR], 2.68; 95%CI, 1.56-4.60)

    PMID 33772933 · one of two readings recorded this

  • length of stay, difference in medians

    no effect, delta = 1.11, 95% CI -2.08 to 4.31, p = 0.49, p = 0.49

    Not recorded as a finding: setting and unit not stated in the abstract, so cannot be mapped onto hospital-length-of-stay with its setting requirement

    The use of AZM was not associated with need for invasive mechanical ventilation (OR = 0.96, 95% CI 0.49-1.87, p = 0.85) and length of stay (Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49).

    PMID 34077600 · one of two readings recorded this

  • length of stay, pooled difference in medians

    no effect, Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49, p = 0.49

    Not recorded as a finding: abstract does not say hospital or ICU stay, so hospital-length-of-stay setting and unit are unstated

    The use of AZM was not associated with need for invasive mechanical ventilation (OR = 0.96, 95% CI 0.49-1.87, p = 0.85) and length of stay (Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49).

    PMID 34077600 · one of two readings recorded this

  • length of stay

    no effect, p = 0.49

    length of stay (Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49)

    PMID 34077600 · one of two readings recorded this

  • mortality (deaths)

    There were 657/3100 (21.2%) and 1244/5654 (22%) deaths among patients randomized to AZM and standard of care, respectively

    PMID 34077600 · one of two readings recorded this

  • mortality (deaths)

    There were 657/3100 (21.2%) and 1244/5654 (22%) deaths among patients randomized to AZM and standard of care, respectively

    PMID 34077600 · one of two readings recorded this

  • mortality

    no effect, p = 0.317

    The use of AZM was not associated with mortality in Covid-19 patients (OR = 0.96, 95% CI 0.88-1.05, p = 0.317 based on the random-effect meta-analysis)

    PMID 34077600 · one of two readings recorded this

  • need for invasive mechanical ventilation, pooled OR

    no effect, OR = 0.96, 95% CI 0.49-1.87, p = 0.85, p = 0.85

    Not recorded as a finding: proportion needing ventilation is not the node's duration of mechanical ventilation

    The use of AZM was not associated with need for invasive mechanical ventilation (OR = 0.96, 95% CI 0.49-1.87, p = 0.85) and length of stay (Δ = 1.11, 95% CI -2.08 to 4.31, p = 0.49).

    PMID 34077600 · both readings recorded this

  • need for invasive mechanical ventilation

    no effect, p = 0.85

    The use of AZM was not associated with need for invasive mechanical ventilation (OR = 0.96, 95% CI 0.49-1.87, p = 0.85)

    PMID 34077600 · one of two readings recorded this

  • TNF-α

    decreases, p = 0.00001

    TNF-α (MD = -9.09, 95% CI[-10.91, -7.27], P<0.00001)

    PMID 34255785 · one of two readings recorded this

  • IL-6

    decreases, p = 0.0001

    For IL-6 (MD = -8.35, 95% CI[-12.31, -4.4], P<0.0001)

    PMID 34255785 · one of two readings recorded this

  • IL-8

    decreases, p = 0.00001

    IL-8 (MD = -4.49, 95% CI[-5.12, -3.87], P<0.00001)

    PMID 34255785 · one of two readings recorded this

  • adverse rate (incidence)

    decreases, p = 0.00001

    (MD = 0.44, 95% CI[0.35, 0.56], P<0.00001)

    PMID 34255785 · one of two readings recorded this

  • adverse rate (incidence)

    decreases, p = 0.00001

    (MD = 0.36, 95% CI [0.27, 0.47], P < 0.00001)

    PMID 34255785 · one of two readings recorded this

  • adverse rate (incidence)

    no effect, p = 0.59

    (MD = 0.88, 95% CI[0.54, 1.41], P = 0.59)

    PMID 34255785 · one of two readings recorded this

  • adverse rate, subgroup heterogeneity by mode of administration

    p = 0.001

    the mode of administration (P = 0.001, I2 = 90.3%)

    PMID 34255785 · one of two readings recorded this

  • average hospitalization time

    decreases, p = 0.00001

    (MD = -4.19, 95% CI[-5.03, -3.34], P<0.00001)

    PMID 34255785 · one of two readings recorded this

  • CD3+ T-lymphocytes

    increases, p = 0.00001

    For CD3+ T-lymphocytes (MD = 6.68, 95% CI[5.29, 8.06], P<0.00001)

    PMID 34255785 · one of two readings recorded this

  • CD4+/CD8+ ratio

    increases, p = 0.0002

    CD4/CD8 (MD = 0.31, 95% CI[0.14, 0.47], P = 0.0002)

    PMID 34255785 · one of two readings recorded this

  • CD4+ T-lymphocytes

    increases, p = 0.00001

    CD4+ T-lymphocytes (MD = 4.78, 95% CI[3.76, 5.81], P<0.00001)

    PMID 34255785 · one of two readings recorded this

  • CD8+ T-lymphocytes

    decreases, p = 0.00001

    CD8+ T-lymphocytes (MD = -4.52, 95% CI[-5.28, -3.77], P<0.00001)

    PMID 34255785 · one of two readings recorded this

  • disappearance time of cough, subgroup analysis by age

    p = 0.0002

    age (P = 0.0002, I2 = 93%)

    PMID 34255785 · one of two readings recorded this

  • disappearance time of cough, subgroup analysis by course of disease

    p = 0.0001

    course of disease (P = 0.0001, I2 = 93.2)

    PMID 34255785 · one of two readings recorded this

  • disappearance time of cough, subgroup analysis by drug delivery way

    p = 0.02

    drug delivery way (P = 0.02, I2 = 82.3%)

    PMID 34255785 · one of two readings recorded this

  • disappearance time of cough

    decreases, p = 0.00001

    (MD = -2.95, 95% CI [- 3.55, -2.34], P < 0.00001)

    PMID 34255785 · one of two readings recorded this

  • disappearance time of fever, sensitivity analysis excluding one study

    decreases

    (MD = -1.51, 95% CI [- 1.74, -1.28])

    PMID 34255785 · one of two readings recorded this

  • disappearance time of fever

    decreases, p = 0.00001

    (MD = -1.72, 95% CI[-2.47, -0.97], P<0.00001)

    PMID 34255785 · one of two readings recorded this

  • disappearance time of pulmonary rales, sensitivity analysis excluding Lu 2017

    decreases

    (MD = -1.95, 95% CI[-2.47, -1.44])

    PMID 34255785 · one of two readings recorded this

  • disappearance time of pulmonary rales, subgroup analysis by age

    p = 0.0004

    age (P = 0.0004, I2 = 92.1%)

    PMID 34255785 · one of two readings recorded this

  • disappearance time of pulmonary rales, subgroup analysis by course of disease

    p = 0.16

    course of disease (P = 0.16, I2 = 49.7%)

    PMID 34255785 · one of two readings recorded this

  • disappearance time of pulmonary rales, subgroup analysis by drug delivery way

    p = 0.00004

    drug delivery way (P = 0.00004, I2 = 92.1%)

    PMID 34255785 · one of two readings recorded this

  • disappearance time of pulmonary rales

    decreases, p = 0.00001

    (MD = -2.13, 95% CI[-2.88, -1.38], P<0.00001)

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of cough

    decreases, p = 0.0007

    Age | -0.6432 | 0.0007 | [-1.0165, -0.2698] ***

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of cough

    decreases, p = 0.0004

    Course of disease | -0.331 | 0.0004 | [-0.5148, -0.1473] ***

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of cough

    no effect, p = 0.0892

    Course of treatment | 0.0464 | 0.0892 | [-0.0071, 0.1000]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of cough

    no effect, p = 0.4229

    Dosage form | 0.609 | 0.4229 | [-2.0987, 0.8806]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of cough

    increases, p = 0.0477

    Drug delivery way | 1.1272 | 0.0477 | [0.0112, 2.2432] *

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of cough

    no effect, p = 0.0758

    Disappearance time of cough | Sample size | 0.0113 | 0.0758 | [-0.0012, 0.0238]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of fever

    no effect, p = 0.3684

    Age | -0.2208 | 0.3684 | [-0.7018, 0.2603]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of fever

    no effect, p = 0.7877

    Course of disease | -0.0406 | 0.7877 | [-0.3360, 0.2548]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of fever

    no effect, p = 0.3308

    Course of treatment | 0.0261 | 0.3308 | [-0.0265, 0.0787]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of fever

    no effect, p = 0.6281

    Dosage form | -0.5253 | 0.6281 | [-2.6512, 1.6005]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of fever

    no effect, p = 0.5857

    Drug delivery way | -0.5795 | 0.5857 | [-2.6637, 1.5046]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of fever

    no effect, p = 0.5055

    Disappearance time of fever | Sample size | -0.0051 | 0.5055 | [-0.0202, 0.0100]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of pulmonary rales

    no effect, p = 0.5357

    Age | -0.0765 | 0.5357 | [-0.3184, 0.1655]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of pulmonary rales

    increases, p = 0.0098

    Course of disease | 0.5018 | 0.0098 | [0.1212, 0.8824] **

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of pulmonary rales

    no effect, p = 0.1061

    Course of treatment | -0.074 | 0.1061 | [-0.1639, 0.0158]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of pulmonary rales

    no effect, p = 0.0824

    Dosage form | 1.9003 | 0.0824 | [-0.2443, 4.0449]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of pulmonary rales

    decreases, p = 0.0119

    Drug delivery way | -1.0331 | 0.0119 | [-1.8384, -0.2278] *

    PMID 34255785 · one of two readings recorded this

  • meta-regression of disappearance time of pulmonary rales

    decreases, p = 0.0001

    Disappearance time of pulmonary rale | Sample size | -0.026 | <0.0001 | [-0.0356, -0.0165] ***

    PMID 34255785 · one of two readings recorded this

  • meta-regression of response rate

    no effect, p = 0.4422

    Age | -0.0071 | 0.4422 | [-0.0251, 0.0109]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of response rate

    decreases, p = 0.0051

    Course of disease | -0.0147 | 0.0051 | [-0.0249, -0.0044] **

    PMID 34255785 · one of two readings recorded this

  • meta-regression of response rate

    no effect, p = 0.1414

    Course of treatment | -0.0028 | 0.1414 | [-0.0065, 0.0009]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of response rate

    no effect, p = 0.1388

    Dosage form | -0.077 | 0.1388 | [-0.1790, 0.0249]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of response rate

    no effect, p = 0.4143

    Drug delivery way | 0.0369 | 0.4143 | [-0.0517, 0.1255]

    PMID 34255785 · one of two readings recorded this

  • meta-regression of response rate

    no effect, p = 0.2071

    Response rate | Sample size | -0.0004 | 0.2071 | [-0.001,0.0002]

    PMID 34255785 · one of two readings recorded this

  • response rate, SHL + azithromycin vs azithromycin alone

    increases, p = 0.00001

    (RR = 1.14, 95% CI[1.11, 1.18], P<0.00001)

    PMID 34255785 · one of two readings recorded this

  • response rate, subgroup analysis by course of disease

    no effect, p = 0.39

    the course of the disease was not the source of heterogeneity (P = 0.39, I2 = 0%)

    PMID 34255785 · one of two readings recorded this

  • response rate

    n = 1442

    1374 of 1442 patients (95.28%) receiving the SHL combined with azithromycin and 1186 of 1442 patients (82.25%) receiving azithromycin alone

    PMID 34255785 · one of two readings recorded this

  • response rate

    n = 1442

    1374 of 1442 patients (95.28%) receiving the SHL combined with azithromycin and 1186 of 1442 patients (82.25%) receiving azithromycin alone

    PMID 34255785 · one of two readings recorded this

  • mortality in patients with COVID-19, pooled odds ratio, azithromycin versus no azithromycin; abstract only, follow-up horizon not stated

    no effect, overall OR: 0.95 (0.79-1.13)

    Not recorded as a finding: the paper never states the instrument the node requires

    The meta-analysis showed no difference in mortality for those treated with or without azithromycin, in observational studies [OR: 0.90 (0.66-1.24)], RCTs [OR: 0.97 (0.87-1.08)] and also when both types of studies were pooled together [with an overall OR: 0.95 (0.79-1.13)].

    PMID 34791330 · one of two readings recorded this

  • mortality

    no effect

    also when both types of studies were pooled together [with an overall OR: 0.95 (0.79-1.13)]

    PMID 34791330 · one of two readings recorded this

  • mortality

    no effect

    in observational studies [OR: 0.90 (0.66-1.24)]

    PMID 34791330 · one of two readings recorded this

  • mortality

    no effect

    RCTs [OR: 0.97 (0.87-1.08)]

    PMID 34791330 · one of two readings recorded this

  • FEV1 (%) change from baseline, short term (12 weeks or less), pooled pre/post azithromycin

    MD: 10.65; 95% CI = 1.63-19.67; P =.02, p = 0.02

    Not recorded as a finding: within-arm before/after change, not a between-arm contrast; also a subgroup by duration

    Pooled analysis showed a significant difference in FEV1 (%) change values between pre- and posttreatment of azithromycin for short term (MD: 10.65; 95% CI = 1.63–19.67; P =.02), with high heterogeneity (I2 = 86.40%).

    PMID 35839027 · one of two readings recorded this

  • FEV1 (%) compared to baseline, change before vs after azithromycin

    no effect

    FEV1 (%) compared to baseline (≤12 wk) | HSCT | 2 | 10.28 (–11.01 to 31.57) | 91.13 | 0

    PMID 35839027 · one of two readings recorded this

  • FEV1 (%) compared to baseline, change before vs after azithromycin

    no effect

    LTx | 4 | 10.93 (–0.57 to 22.43) | 87.56 | 0

    PMID 35839027 · one of two readings recorded this

  • FEV1 (%) compared to baseline, change before vs after azithromycin

    increases, p = 0.02

    for short term (MD: 10.65; 95% CI = 1.63–19.67; P =.02)

    PMID 35839027 · one of two readings recorded this

  • FEV1 (L) change before versus after azithromycin, mid-term 12-24 weeks, pooled MD

    increases, MD 0.22 L (95% CI = 0.05 to 0.39; P =.01; I2 = 41.68%), p = 0.01

    Not recorded as a finding: within-arm pre/post change pooled from mostly uncontrolled case series, not a between-arm contrast

    The results of the pooled analysis showed an increasing trend in FEV1 (L) between pre– and post–azithromycin treatment, specifically at the mid-term, where the pooled MD in FEV1 (L) was increased by 0.22 L (95% CI = 0.05 to 0.39; P =.01; I2 = 41.68%), manifesting considerable clinical significance.

    PMID 35839027 · one of two readings recorded this

  • FEV1 (L) change before vs after azithromycin

    no effect

    FEV1 (L) (≤12 wk) | Transplant types | HSCT | 2 | 0.09 (–020 to 0.38) | 0 |.37

    PMID 35839027 · one of two readings recorded this

  • FEV1 (L) change before vs after azithromycin

    increases

    LTx | 5 | 0.16 (0.08–0.24) | 14.58 |.32

    PMID 35839027 · one of two readings recorded this

  • FEV1 (L) change before vs after azithromycin

    no effect, p = 0.65

    However, this improvement seemed not to be sustained (MD = 0.11 L; 95% CI = −0.39 to 0.62; P =.65; I2 = 91.00%)

    PMID 35839027 · one of two readings recorded this

  • FEV1 (L) change before vs after azithromycin

    increases, p = 0.01

    the pooled MD in FEV1 (L) was increased by 0.22 L (95% CI = 0.05 to 0.39; P =.01; I2 = 41.68%)

    PMID 35839027 · one of two readings recorded this

  • FEV1% predicted change before vs after azithromycin

    no effect

    Azithromycin | 3 | 5.80 (–4.49 to 16.09) | 92.57 | 0

    PMID 35839027 · one of two readings recorded this

  • FEV1% predicted change before vs after azithromycin

    no effect

    Azithromycin | 2 | 2.08 (–2.30 to 6.46) | 56.14 | 0

    PMID 35839027 · one of two readings recorded this

  • FEV1% predicted change before vs after azithromycin

    no effect

    FEV1% predicted (12–24 wk) | HSCT | 2 | 1.93 (–1.36 to 5.21) | 0 |.96

    PMID 35839027 · one of two readings recorded this

  • FEV1% predicted change before vs after azithromycin

    no effect

    FEV1% predicted (≤12 wk) | HSCT | 1 | 3.68 (–0.90 to 8.26) | – | –

    PMID 35839027 · one of two readings recorded this

  • FEV1% predicted change before vs after azithromycin

    no effect

    LTx | 3 | 5.80 (–4.49 to 16.09) | 92.57 | 0

    PMID 35839027 · one of two readings recorded this

  • FEV1% predicted change before vs after azithromycin

    no effect

    LTx | 2 | 2.08 (–2.30 to 6.46) | 56.14 | 0

    PMID 35839027 · one of two readings recorded this

  • FEV1% predicted change before vs after azithromycin

    no effect

    FEV1% predicted (12–24 wk) | FAM | 2 | 1.93 (–1.36 to 5.21) | 0 |.96

    PMID 35839027 · one of two readings recorded this

  • FEV1% predicted change before vs after azithromycin

    no effect

    FEV1% predicted (≤12 wk) | Administration regimen | FAM | 1 | 3.68 (–0.90 to 8.26) | – | –

    PMID 35839027 · one of two readings recorded this

  • FEV1% predicted change before vs after azithromycin

    increases, p = 0.01

    Pooled analysis showed a significant increase in the predicted FEV1 (%) (MD: 2.99; 95% CI = 0.70–5.27; P =.01; I2 = 14.77%)

    PMID 35839027 · one of two readings recorded this

  • FEV1% predicted, short term (12 weeks or less), pooled pre/post azithromycin

    increases, MD: 2.99; 95% CI = 0.70-5.27; P =.01, p = 0.01

    Not recorded as a finding: within-arm before/after change, not a between-arm contrast; also a subgroup by duration

    Pooled analysis showed a significant increase in the predicted FEV1 (%) (MD: 2.99; 95% CI = 0.70–5.27; P =.01; I2 = 14.77%) between pre– and post–azithromycin short-term treatment.

    PMID 35839027 · one of two readings recorded this

  • survival (risk of death)

    decreases

    the risk of death was significantly reduced with azithromycin treatment compared with nonazithromycin (HR = 0.26; 95% CI = 0.17–0.40; P =.00)

    PMID 35839027 · one of two readings recorded this

  • carriage of pathogenic organisms (Streptococcus pneumoniae, gut Campylobacter)

    decreases

    The carriage of pathogenic organisms such as Streptococcus pneumoniae and gut Campylobacter species was reduced

    PMID 35970284 · one of two readings recorded this

  • child mortality after azithromycin mass drug administration (abstract only; follow-up horizon and comparator not stated)

    decreases

    Not recorded as a finding: no estimate is reported anywhere

    Azithromycin MDA reduced child mortality, and quarterly MDA may be most beneficial for reducing child mortality.

    PMID 35970284 · one of two readings recorded this

  • child mortality after azithromycin mass drug administration, pooled across six studies; abstract only

    decreases

    Not recorded as a finding: the paper never states the instrument the node requires

    Azithromycin MDA reduced child mortality, and quarterly MDA may be most beneficial for reducing child mortality.

    PMID 35970284 · one of two readings recorded this

  • child mortality

    decreases

    Azithromycin MDA reduced child mortality, and quarterly MDA may be most beneficial for reducing child mortality

    PMID 35970284 · one of two readings recorded this

  • diarrhea

    decreases

    Azithromycin MDA was associated with a lower risk of respiratory tract infections and diarrhea

    PMID 35970284 · one of two readings recorded this

  • fever, vomiting and headache

    decreases

    Additionally, it was associated with a lower risk of fever, vomiting, and headache

    PMID 35970284 · one of two readings recorded this

  • malaria parasitemia

    no effect

    No association was observed between azithromycin MDA and malaria parasitemia (rate ratio: 0.71, 95% confidence interval: 0.43-1.15)

    PMID 35970284 · one of two readings recorded this

  • nutritional improvement in children

    no effect

    Moreover, no association was observed between azithromycin MDA and nutritional improvement in children

    PMID 35970284 · one of two readings recorded this

  • respiratory tract infections

    decreases

    Azithromycin MDA was associated with a lower risk of respiratory tract infections and diarrhea

    PMID 35970284 · one of two readings recorded this

  • adverse events

    no effect, p = 0.07

    adverse events (OR = 0.90; 95% CI 0.80–1.01; P = 0.07

    PMID 36221151 · one of two readings recorded this

  • FEV1

    no effect, p = 0.39

    no obvious influence on FEV1 (SMD = 0.29; 95% CI − 0.37 to 0.96; P = 0.39

    PMID 36221151 · one of two readings recorded this

  • free of exacerbation

    increases, p = 0.001

    significantly improved free of exacerbation (OR = 3.66; 95% CI 1.69–7.93; P = 0.001)

    PMID 36221151 · one of two readings recorded this

  • nausea or vomiting

    no effect, p = 0.5

    nausea or vomiting (OR = 1.29; 95% CI 0.61–2.69; P = 0.50

    PMID 36221151 · one of two readings recorded this

  • number of pulmonary exacerbations

    decreases, p = 0.00001

    substantially reduce the number of pulmonary exacerbations (SMD = − 0.87; 95% CI − 1.21 to − 0.54; P < 0.00001

    PMID 36221151 · one of two readings recorded this

  • pulmonary exacerbations

    decreases, p = 0.001

    reduced pulmonary exacerbations (OR = 0.27; 95% CI 0.13–0.59; P = 0.001)

    PMID 36221151 · one of two readings recorded this

  • score on St George’s respiratory questionnaire

    no effect, p = 0.69

    score on St George’s respiratory questionnaire (SMD = − 1.02; 95% CI − 6.11 to 4.06; P = 0.69

    PMID 36221151 · one of two readings recorded this

  • azithromycin resistance, between-study heterogeneity

    p = 0.01

    (I2=98.76%; P=0.01) was observed between

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance, countries with >5% resistant specimens

    n = 51

    Among 51 countries reporting resistance data for azithromycin, 22

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance rate, difference between continents

    p = 0.01

    between different continents (P <0.01)

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance rate, method used for AST and interpretation of resistance

    no effect, p = 0.36

    and the interpretation of resistance (P=0.36)

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance rate, South America versus Africa

    Africa (9.2% vs. 5.3%)

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance rate, South America versus Asia

    higher in South America than Asia (9.2% vs. 6.3%)

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance rate, South America versus Europe

    Europe (9.2% vs. 5.8%)

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance rate, South America versus North America

    North America (9.2% vs. 2.1%,)

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance, worldwide pooled rate (WPR)

    n = 165172

    NG isolates; the WPR was 6% (95% CI 5%-7%) with substantial heterogeneity

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance, WPR

    1988-2013 (WPR 2.31%; 95% CI 1.40%-3.40%)

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance, WPR

    2014-2018 (WPR 6.85%; 95% CI

    PMID 36568835 · one of two readings recorded this

  • azithromycin resistance, WPR

    increases

    2019-2021 (WPR 7.25%; 95% CI 5.62%-9.06%)

    PMID 36568835 · one of two readings recorded this

  • erythromycin resistance, between-study heterogeneity

    p = 0.01

    heterogeneity (I2=98.69%, P< 0.01) was observed

    PMID 36568835 · one of two readings recorded this

  • erythromycin resistance prevalence

    prevalence of erythromycin resistance notably increased from 17.16% (95% CI

    PMID 36568835 · one of two readings recorded this

  • erythromycin resistance prevalence

    increases, n = 1569

    6.08-32.12) of 18 strains 1988-2013 reaching 72% (95% CI 50.61-87.93) of 1,569

    PMID 36568835 · one of two readings recorded this

  • erythromycin resistance rate, difference between continents

    no effect, p = 0.83

    continents (P=0.83)

    PMID 36568835 · one of two readings recorded this

  • erythromycin resistance rate, method used for AST

    no effect, p = 0.08

    method used for AST (P=0.08)

    PMID 36568835 · one of two readings recorded this

  • erythromycin resistance, worldwide pooled rate (WPR)

    n = 13161

    13,161 NG isolates; the WPR was 21% (95% CI 13%-29%) with substantial

    PMID 36568835 · one of two readings recorded this

  • publication bias (Egger's test)

    no effect, p = 0.297

    Egger’s test showed no obvious publication bias in the rate of azithromycin treatment efficiency (p = 0.297)

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 50

    Škerk 2000 | Croatia | 2000 | 44 | 50 | 0.5 g | qd | po | 6d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 30

    Skerk 2000 | Croatia | 2000 | 17 | 30 | 0.5 g | qd | po | 6d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 21

    Fatih Sendag 2000 | Turkey | 2000 | 15 | 21 | 1 g | once | po | 1d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 30

    Skerk 2000 | Croatia | 2000 | 28 | 30 | 1 g | Once | po | 1d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 14

    Steingrimssoir Olafnr 1990 | USA | 1990 | 11 | 14 | 1 g | once | po | 1d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 90

    Wen-E Liu 2013 | China | 2013 | 13 | 90 | 1 g | qd | po | 7d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 5

    Steingrimssoir Olafnr 1990 | USA | 1990 | 5 | 5 | 500 mg d1, 250 mg d2–3 | qd | po | 3d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 98

    Wen-E Liu 2013 | China | 2013 | 20 | 98 | Chinese Traditional Medicine | 10 g | tid | po | 14d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 30

    Skerk 2000 | Croatia | 2000 | 28 | 30 | Doxycycline | 100 mg | bid | po | 14d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 22

    Fatih Sendag 2000 | Turkey | 2000 | 17 | 22 | Doxycycline | 100 mg | bid | po | 7d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 64

    Škerk 2000 | Croatia | 2000 | 47 | 64 | Doxycycline | 100 mg | bid | po | 7d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 30

    Skerk 2000 | Croatia | 2000 | 28 | 30 | Doxycycline | 100 mg | bid | po | 7d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 12

    Steingrimssoir Olafnr 1990 | USA | 1990 | 9 | 12 | Doxycycline | bid | po | 1d

    PMID 36927441 · one of two readings recorded this

  • treatment response cases

    n = 16

    Steingrimssoir Olafnr 1990 | USA | 1990 | 12 | 16 | Doxycycline | bid | po | 7d

    PMID 36927441 · one of two readings recorded this

  • treatment response (cure) of Ureaplasma urealyticum infection

    no effect, n = 512

    The fixed effect of RR was 1.03 [0.94, 1.12], while the random effect of RR was 0.98 [0.80, 1.20]

    PMID 36927441 · one of two readings recorded this

  • treatment response (cure) of Ureaplasma urealyticum infection

    no effect, n = 512

    The fixed effect of RR was 1.03 [0.94, 1.12], while the random effect of RR was 0.98 [0.80, 1.20]

    PMID 36927441 · one of two readings recorded this

  • treatment response (cure) of Ureaplasma urealyticum infection

    no effect

    The fixed effect of RR in subgroup of a single dose of 1 g was 0.99 [0.88, 1.12] and in subgroup of 0.5 g QD for 7 days was 1.02 [0.87, 1.20]

    PMID 36927441 · one of two readings recorded this

  • treatment response (cure) of Ureaplasma urealyticum infection

    no effect

    The fixed effect of RR in subgroup of a single dose of 1 g was 0.99 [0.88, 1.12] and in subgroup of 0.5 g QD for 7 days was 1.02 [0.87, 1.20]

    PMID 36927441 · one of two readings recorded this

  • treatment response (cure) of Ureaplasma urealyticum infection

    no effect

    The fixed effect of RR was 1.04 [0.95, 1.13]

    PMID 36927441 · one of two readings recorded this

  • treatment response (microbiological cure) of Ureaplasma urealyticum infection in the female reproductive tract, pooled risk ratio

    no effect

    Not recorded as a finding: the comparison was against another active treatment

    Compared to other antibiotics, azithromycin has a comparable therapeutic effect on Ureaplasma urealyticum infection.

    PMID 36927441 · one of two readings recorded this

  • treatment response (mycoplasma cure) of Ureaplasma urealyticum infection in the female reproductive tract, pooled risk ratio

    no effect

    Not recorded as a finding: the comparison was against another active treatment

    Compared to other antibiotics, azithromycin has a comparable therapeutic effect on Ureaplasma urealyticum infection.

    PMID 36927441 · one of two readings recorded this

  • induction of arrhythmia

    no effect, n = 9723

    induction of arrhythmia [(n= 9,723 patients) OR= 1.21 (95% CI: 0.63-2.32)

    PMID 36996755 · one of two readings recorded this

  • mortality

    no effect, n = 27204

    statistically insignificant reduction in mortality [(n= 27,204 patients) OR= 0.77 (95% CI: 0.51-1.16)

    PMID 36996755 · one of two readings recorded this

  • QTc prolongation

    no effect, n = 6534

    QTc prolongation (a surrogate for torsadogenic effect) [(n= 6,534 patients) OR= 0.62 (95% CI: 0.23-1.73)

    PMID 36996755 · one of two readings recorded this

  • requirement of mechanical ventilation

    no effect, n = 14908

    requirement of mechanical ventilation [(n= 14,908 patients) OR= 1.4 (95% CI: 0.58-3.35)

    PMID 36996755 · one of two readings recorded this

  • adverse reaction incidence, in children with respiratory disease treated with azithromycin

    decreases, OR = 0.42, 95% CI 0.12-0.72

    Not recorded as a finding: the comparison was against another active treatment

    The results of meta-analysis showed that the incidence of adverse reactions after AZM treatment was 24.20%, which was lower than 48.05% in the control group (OR = 0.42, 95% CI 0.12-0.72, P < .001).

    PMID 38050289 · one of two readings recorded this

  • adverse reaction incidence, intravenous administration subgroup

    decreases, OR = 0.57, 95% CI 0.12-0.84

    In the subgroup of intravenous administration, AZM had a lower the incidence of adverse reactions (OR = 0.57, 95% CI 0.12-0.84, P = .003).

    PMID 38050289 · one of two readings recorded this

  • adverse reaction incidence, oral administration subgroup

    decreases, OR = 0.45, 95% CI 0.13-0.69

    In the subgroup of oral administration, AZM had a lower the incidence of adverse reactions (OR = 0.45, 95% CI 0.13-0.69 P < .001).

    PMID 38050289 · one of two readings recorded this

  • adverse reaction incidence, sequential therapy subgroup

    decreases, OR = 0.29, 95% CI 0.09-0.60

    In the subgroup of sequential therapy, AZM had a lower incidence of adverse reactions in sequential therapy (OR = 0.29, 95% CI 0.09-0.60, P < .001).

    PMID 38050289 · one of two readings recorded this

  • incidence of adverse reactions after azithromycin (AZM) treatment in pediatric respiratory disease RCTs, vs a control group whose composition the abstract never states

    decreases, OR = 0.42, 95% CI 0.12-0.72, P < .001

    Not recorded as a finding: another reason, stated per paper

    The results of meta-analysis showed that the incidence of adverse reactions after AZM treatment was 24.20%, which was lower than 48.05% in the control group (OR = 0.42, 95% CI 0.12-0.72, P < .001).

    PMID 38050289 · one of two readings recorded this

  • incidence of adverse reactions after azithromycin treatment, pediatric respiratory disease RCTs

    decreases, OR = 0.42, 95% CI 0.12-0.72, P < .001

    The results of meta-analysis showed that the incidence of adverse reactions after AZM treatment was 24.20%, which was lower than 48.05% in the control group (OR = 0.42, 95% CI 0.12-0.72, P < .001).

    PMID 38050289 · one of two readings recorded this

  • incidence of adverse reactions, intravenous administration subgroup

    decreases, OR = 0.57, 95% CI 0.12-0.84, P = .003, p = 0.003

    In the subgroup of intravenous administration, AZM had a lower the incidence of adverse reactions (OR = 0.57, 95% CI 0.12-0.84, P = .003).

    PMID 38050289 · one of two readings recorded this

  • incidence of adverse reactions, oral administration subgroup

    decreases, OR = 0.45, 95% CI 0.13-0.69, P < .001

    In the subgroup of oral administration, AZM had a lower the incidence of adverse reactions (OR = 0.45, 95% CI 0.13-0.69 P < .001).

    PMID 38050289 · one of two readings recorded this

  • incidence of adverse reactions, sequential therapy subgroup

    decreases, OR = 0.29, 95% CI 0.09-0.60, P < .001

    In the subgroup of sequential therapy, AZM had a lower incidence of adverse reactions in sequential therapy (OR = 0.29, 95% CI 0.09-0.60, P < .001).

    PMID 38050289 · one of two readings recorded this

  • overall adverse reaction incidence

    decreases, OR = 0.42, 95% CI 0.12-0.72

    The results of meta-analysis showed that the incidence of adverse reactions after AZM treatment was 24.20%, which was lower than 48.05% in the control group (OR = 0.42, 95% CI 0.12-0.72, P < .001).

    PMID 38050289 · one of two readings recorded this

  • clinically diagnosed asthma

    no effect, RR 0.94 (CI 0.29-3.10), n = 227

    Not recorded as a finding: no_outcome_node: no node for asthma diagnosis incidence

    Pooled estimate for asthma did not show any difference between the groups (0.94, CI 0.29–3.10; Supplementary Fig. 3).

    PMID 38066246 · one of two readings recorded this

  • gastrointestinal adverse events

    no effect, RD 2.0% (CI -1.0% to 5.0%), n = 268

    Two studies (268 children) focused on gastrointestinal adverse events and did not find significant difference between the groups (RD 2.0%, CI –1.0% to 5.0%; Supplementary Fig. 4).

    PMID 38066246 · both readings recorded this

  • hospital readmission (pooled across follow-up timepoints)

    no effect, risk ratio 1.14 (CI 0.82–1.60)

    Not recorded as a finding: no outcome node in the supplied list covers hospital readmission rate

    When all of the previous timepoints were pooled together the risk ratio for readmission to hospital was 1.14 (CI 0.82–1.60; Supplementary Fig. 1).

    PMID 38066246 · one of two readings recorded this

  • Hospital readmission (pooled timepoints)

    no effect, RR 1.14 (CI 0.82-1.60)

    When all of the previous timepoints were pooled together the risk ratio for readmission to hospital was 1.14 (CI 0.82–1.60; Supplementary Fig. 1).

    PMID 38066246 · one of two readings recorded this

  • hospital readmission

    RR 1.14 (CI 0.82-1.60), n = 585

    Not recorded as a finding: no_outcome_node: no node for hospital readmission rate

    When all of the previous timepoints were pooled together the risk ratio for readmission to hospital was 1.14 (CI 0.82–1.60; Supplementary Fig. 1).

    PMID 38066246 · one of two readings recorded this

  • need for paediatric intensive care unit (PICU) admission

    no effect, pooled RD 0.0%, CI –2.0% to 2.0%, n = 446

    Not recorded as a finding: no outcome node in the supplied list covers PICU admission (distinct from ICU length-of-stay)

    Four studies (446 children) analyzed the need for PICU admission and one child in the azithromycin group (0.5%) and four children in the control group (1.8%) were admitted to PICU (pooled RD 0.0%, CI –2.0% to 2.0%; Fig. 3).

    PMID 38066246 · one of two readings recorded this

  • Need for PICU admission

    no effect, pooled RD 0.0% (CI -2.0% to 2.0%), n = 446

    Four studies (446 children) analyzed the need for PICU admission and one child in the azithromycin group (0.5%) and four children in the control group (1.8%) were admitted to PICU (pooled RD 0.0%, CI –2.0% to 2.0%; Fig. 3).

    PMID 38066246 · one of two readings recorded this

  • overall length of hospitalization

    decreases, n = 325

    Three studies with 325 children analyzed the overall length of hospitalization period, and the mean difference was -0.27 days (CI –0.47 to –0.07 days; Fig. 4) favoring azithromycin group.

    PMID 38066246 · both readings recorded this

  • recurrence of wheezing episode

    RR 0.84 (CI 0.45-1.56), n = 297

    Not recorded as a finding: no_outcome_node: no node for wheezing recurrence

    After pooling of these studies, the risk ratio for at least one recurrence of wheezing episode was 0.84 (CI 0.45–1.56; Supplementary Fig. 2).

    PMID 38066246 · one of two readings recorded this

  • recurrence of wheezing (pooled across follow-up timepoints)

    no effect, risk ratio 0.84 (CI 0.45–1.56)

    Not recorded as a finding: no outcome node in the supplied list covers recurrence of wheezing

    After pooling of these studies, the risk ratio for at least one recurrence of wheezing episode was 0.84 (CI 0.45–1.56; Supplementary Fig. 2).

    PMID 38066246 · one of two readings recorded this

  • Recurrence of wheezing (pooled timepoints)

    no effect, RR 0.84 (CI 0.45-1.56)

    After pooling of these studies, the risk ratio for at least one recurrence of wheezing episode was 0.84 (CI 0.45–1.56; Supplementary Fig. 2).

    PMID 38066246 · one of two readings recorded this

  • clinical failure, mortality, treatment-related adverse effects

    no effect

    Additionally, there was no difference between the two arms concerning clinical failure, mortality and treatment-related adverse effects.

    PMID 38110855 · one of two readings recorded this

  • clinical failure rate, scrub typhus, doxycycline vs azithromycin

    no effect

    Additionally, there was no difference between the two arms concerning clinical failure, mortality and treatment-related adverse effects.

    PMID 38110855 · one of two readings recorded this

  • mortality, scrub typhus, doxycycline vs azithromycin

    no effect

    Additionally, there was no difference between the two arms concerning clinical failure, mortality and treatment-related adverse effects.

    PMID 38110855 · one of two readings recorded this

The whole record — 304 rows